Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant for the same disease?

yes no

Laboratory Studies at Diagnosis Questions: 1 - 19

WBC

Known Unknown

1

2 x 109/L (x 103/mm3)

x 106/L

Date sample collected:3 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

4

5 %

Date sample collected:6 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

7

8 %

Date sample collected:9 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

10

Central nervous system

yes no

11

Cerebrospinal fluid (CSF)

Yes No

12

Parenchyma (brain)

Yes No

13

Mediastinum

yes no

14

Skin

yes no

15

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

16

Testes / ovaries

Yes No

17

Other site

yes no

18

Specify other site:19

Pre-HCT or Pre-Infusion Therapy Questions: 20 - 63

Was central nervous system prophylaxis given?

yes no Unknown

20

Cranial irradiation

yes no

21

Craniospinal irradiation

Yes No

22

High-dose methotrexate

yes no

23

Intrathecal therapy (chemotherapy)

yes no

24

Other prophylaxis

yes no

25

Specify prophylaxis:26

Was therapy given?

yes no

27

Line of Therapy (1) Questions: 28 - 63

Purpose of therapy28

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

29

Systemic therapy

yes no

30

Date therapy started

Known Unknown

31

Date started:32 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

33

Date stopped:34 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

35

Number of cycles:36

Specify systemic therapy: (check all that apply for this line of therapy)

Blinatumomab (Blincyto)

Chemotherapy

Dasatinib (Sprycel)

Imatinib (Gleevec)

Inotuzumab

Nilotinib (AMN107, Tasigna)

Ponatinib (Iclusig)

Rituximab (Rituxan, MabThera)

Other systemic therapy

37

Specify other systemic therapy:38

Radiation therapy

yes no

39

Date therapy started

Known Unknown

40

Date started:41 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

42

Date stopped:43 __ __ __ __ - __ __- __ __

Central nervous system

yes no

44

Cranial

yes no

45

Craniospinal

Yes No

46

Other site

yes no

47

Specify other site:48

Cellular therapy (e.g. CAR T-cell)

yes no

49

Best response to line of therapy50

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:51 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

52

Did the recipient relapse following this line of therapy?

yes no

53

Date of relapse:54 __ __ __ __ - __ __- __ __

Central nervous system

yes no

55

Cerebrospinal fluid (CSF)

Yes No

56

Parenchyma (brain)

Yes No

57

Mediastinum

Yes No

58

Skin

yes no

59

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

60

Testes / ovaries

Yes No

61

Other site

yes no

62

Specify other site:63

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 64 - 91

WBC

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

67

68 %

Date sample collected:69 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

70

71 %

Date sample collected:72 __ __ __ __ - __ __- __ __

Was flow cytometry performed?

yes no Unknown

73

Blood

yes no

74

Date sample collected:75 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

76

Specify percent disease detected:77 %

Bone marrow

yes no

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Specify percent disease detected:81 %

Was extramedullary disease present?

yes no Unknown

82

Central nervous system

yes no

83

Cerebrospinal fluid (CSF)

Yes No

84

Parenchyma (brain)

Yes No

85

Mediastinum

yes no

86

Skin

yes no

87

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

88

Testes / ovaries

Yes No

89

Other site

yes no

90

Specify other site:91

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify site(s) of disease:

Specify prophylaxis:

Specify site(s) of radiation therapy:

Specify CNS irradiation:

Specify sites of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen:

Specify site(s) of disease:

Center: CRID: 

Form 2011 R5.0: Acute Lymphoblastic Leukemia (ALL) Pre-Infusion Data

CIBMTR Form 2011 revision 5.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant for the same disease?

yes no

Laboratory Studies at Diagnosis Questions: 1 - 19

WBC

Known Unknown

1

2 x 109/L (x 103/mm3)

x 106/L

Date sample collected:3 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

4

5 %

Date sample collected:6 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

7

8 %

Date sample collected:9 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

10

Central nervous system

yes no

11

Cerebrospinal fluid (CSF)

Yes No

12

Parenchyma (brain)

Yes No

13

Mediastinum

yes no

14

Skin

yes no

15

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

16

Testes / ovaries

Yes No

17

Other site

yes no

18

Specify other site:19

Pre-HCT or Pre-Infusion Therapy Questions: 20 - 63

Was central nervous system prophylaxis given?

yes no Unknown

20

Cranial irradiation

yes no

21

Craniospinal irradiation

Yes No

22

High-dose methotrexate

yes no

23

Intrathecal therapy (chemotherapy)

yes no

24

Other prophylaxis

yes no

25

Specify prophylaxis:26

Was therapy given?

yes no

27

Line of Therapy (1) Questions: 28 - 63

Purpose of therapy28

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

29

Systemic therapy

yes no

30

Date therapy started

Known Unknown

31

Date started:32 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

33

Date stopped:34 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

35

Number of cycles:36

Specify systemic therapy: (check all that apply for this line of therapy)

Blinatumomab (Blincyto)

Chemotherapy

Dasatinib (Sprycel)

Imatinib (Gleevec)

Inotuzumab

Nilotinib (AMN107, Tasigna)

Ponatinib (Iclusig)

Rituximab (Rituxan, MabThera)

Other systemic therapy

37

Specify other systemic therapy:38

Radiation therapy

yes no

39

Date therapy started

Known Unknown

40

Date started:41 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

42

Date stopped:43 __ __ __ __ - __ __- __ __

Central nervous system

yes no

44

Cranial

yes no

45

Craniospinal

Yes No

46

Other site

yes no

47

Specify other site:48

Cellular therapy (e.g. CAR T-cell)

yes no

49

Best response to line of therapy50

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:51 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

52

Did the recipient relapse following this line of therapy?

yes no

53

Date of relapse:54 __ __ __ __ - __ __- __ __

Central nervous system

yes no

55

Cerebrospinal fluid (CSF)

Yes No

56

Parenchyma (brain)

Yes No

57

Mediastinum

Yes No

58

Skin

yes no

59

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

60

Testes / ovaries

Yes No

61

Other site

yes no

62

Specify other site:63

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 64 - 91

WBC

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

67

68 %

Date sample collected:69 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

70

71 %

Date sample collected:72 __ __ __ __ - __ __- __ __

Was flow cytometry performed?

yes no Unknown

73

Blood

yes no

74

Date sample collected:75 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

76

Specify percent disease detected:77 %

Bone marrow

yes no

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Specify percent disease detected:81 %

Was extramedullary disease present?

yes no Unknown

82

Central nervous system

yes no

83

Cerebrospinal fluid (CSF)

Yes No

84

Parenchyma (brain)

Yes No

85

Mediastinum

yes no

86

Skin

yes no

87

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

88

Testes / ovaries

Yes No

89

Other site

yes no

90

Specify other site:91

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify site(s) of disease:

Specify prophylaxis:

Specify site(s) of radiation therapy:

Specify CNS irradiation:

Specify sites of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen:

Specify site(s) of disease:

Center: CRID: 

Form 2011 R5.0: Acute Lymphoblastic Leukemia (ALL) Pre-Infusion Data

CIBMTR Form 2011 revision 5.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant for the same disease?

yes no

Laboratory Studies at Diagnosis Questions: 1 - 19

WBC

Known Unknown

1

2 x 109/L (x 103/mm3)

x 106/L

Date sample collected:3 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

4

5 %

Date sample collected:6 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

7

8 %

Date sample collected:9 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

10

Central nervous system

yes no

11

Cerebrospinal fluid (CSF)

Yes No

12

Parenchyma (brain)

Yes No

13

Mediastinum

yes no

14

Skin

yes no

15

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

16

Testes / ovaries

Yes No

17

Other site

yes no

18

Specify other site:19

Pre-HCT or Pre-Infusion Therapy Questions: 20 - 63

Was central nervous system prophylaxis given?

yes no Unknown

20

Cranial irradiation

yes no

21

Craniospinal irradiation

Yes No

22

High-dose methotrexate

yes no

23

Intrathecal therapy (chemotherapy)

yes no

24

Other prophylaxis

yes no

25

Specify prophylaxis:26

Was therapy given?

yes no

27

Line of Therapy (1) Questions: 28 - 63

Purpose of therapy28

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

29

Systemic therapy

yes no

30

Date therapy started

Known Unknown

31

Date started:32 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

33

Date stopped:34 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

35

Number of cycles:36

Specify systemic therapy: (check all that apply for this line of therapy)

Blinatumomab (Blincyto)

Chemotherapy

Dasatinib (Sprycel)

Imatinib (Gleevec)

Inotuzumab

Nilotinib (AMN107, Tasigna)

Ponatinib (Iclusig)

Rituximab (Rituxan, MabThera)

Other systemic therapy

37

Specify other systemic therapy:38

Radiation therapy

yes no

39

Date therapy started

Known Unknown

40

Date started:41 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

42

Date stopped:43 __ __ __ __ - __ __- __ __

Central nervous system

yes no

44

Cranial

yes no

45

Craniospinal

Yes No

46

Other site

yes no

47

Specify other site:48

Cellular therapy (e.g. CAR T-cell)

yes no

49

Best response to line of therapy50

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:51 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

52

Did the recipient relapse following this line of therapy?

yes no

53

Date of relapse:54 __ __ __ __ - __ __- __ __

Central nervous system

yes no

55

Cerebrospinal fluid (CSF)

Yes No

56

Parenchyma (brain)

Yes No

57

Mediastinum

Yes No

58

Skin

yes no

59

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

60

Testes / ovaries

Yes No

61

Other site

yes no

62

Specify other site:63

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 64 - 91

WBC

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

67

68 %

Date sample collected:69 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

70

71 %

Date sample collected:72 __ __ __ __ - __ __- __ __

Was flow cytometry performed?

yes no Unknown

73

Blood

yes no

74

Date sample collected:75 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

76

Specify percent disease detected:77 %

Bone marrow

yes no

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Specify percent disease detected:81 %

Was extramedullary disease present?

yes no Unknown

82

Central nervous system

yes no

83

Cerebrospinal fluid (CSF)

Yes No

84

Parenchyma (brain)

Yes No

85

Mediastinum

yes no

86

Skin

yes no

87

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

88

Testes / ovaries

Yes No

89

Other site

yes no

90

Specify other site:91

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify site(s) of disease:

Specify prophylaxis:

Specify site(s) of radiation therapy:

Specify CNS irradiation:

Specify sites of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen:

Specify site(s) of disease:

Center: CRID: 

Form 2011 R5.0: Acute Lymphoblastic Leukemia (ALL) Pre-Infusion Data

CIBMTR Form 2011 revision 5.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 4



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Subsequent Transplant or Cellular Therapy

Is this the report of a second or subsequent transplant for the same disease?

yes no

Laboratory Studies at Diagnosis Questions: 1 - 19

WBC

Known Unknown

1

2 x 109/L (x 103/mm3)

x 106/L

Date sample collected:3 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

4

5 %

Date sample collected:6 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

7

8 %

Date sample collected:9 __ __ __ __ - __ __- __ __

Was extramedullary disease present?

yes no Unknown

10

Central nervous system

yes no

11

Cerebrospinal fluid (CSF)

Yes No

12

Parenchyma (brain)

Yes No

13

Mediastinum

yes no

14

Skin

yes no

15

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

16

Testes / ovaries

Yes No

17

Other site

yes no

18

Specify other site:19

Pre-HCT or Pre-Infusion Therapy Questions: 20 - 63

Was central nervous system prophylaxis given?

yes no Unknown

20

Cranial irradiation

yes no

21

Craniospinal irradiation

Yes No

22

High-dose methotrexate

yes no

23

Intrathecal therapy (chemotherapy)

yes no

24

Other prophylaxis

yes no

25

Specify prophylaxis:26

Was therapy given?

yes no

27

Line of Therapy (1) Questions: 28 - 63

Purpose of therapy28

Induction

Consolidation

Maintenance

treatment for disease relapse

Intrathecal therapy

yes no

29

Systemic therapy

yes no

30

Date therapy started

Known Unknown

31

Date started:32 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

33

Date stopped:34 __ __ __ __ - __ __- __ __

Number of cycles

Known Unknown

35

Number of cycles:36

Specify systemic therapy: (check all that apply for this line of therapy)

Blinatumomab (Blincyto)

Chemotherapy

Dasatinib (Sprycel)

Imatinib (Gleevec)

Inotuzumab

Nilotinib (AMN107, Tasigna)

Ponatinib (Iclusig)

Rituximab (Rituxan, MabThera)

Other systemic therapy

37

Specify other systemic therapy:38

Radiation therapy

yes no

39

Date therapy started

Known Unknown

40

Date started:41 __ __ __ __ - __ __- __ __

Date therapy stopped

Known Unknown

42

Date stopped:43 __ __ __ __ - __ __- __ __

Central nervous system

yes no

44

Cranial

yes no

45

Craniospinal

Yes No

46

Other site

yes no

47

Specify other site:48

Cellular therapy (e.g. CAR T-cell)

yes no

49

Best response to line of therapy50

Complete
remission
(CR)

– All of the following response criteria without progression for at least four weeks: < 5% blasts in the bone marrow, no blasts with Auer rods, 
no extramedullary disease (e.g., central nervous system or soft tissue involvement),  ANC of ≥ 1,000/µL, Platelets ≥ 100,000/ µL

Complete remission with incomplete hematologic recovery
(CRi)

- All CR criteria except for residual neutropenia (<1000/µl) and/or thrombocytopenia
(<100,000/µl)

No complete remission

Date assessed:51 __ __ __ __ - __ __- __ __

Was the recipient MRD negative following this line of therapy?

Yes No

52

Did the recipient relapse following this line of therapy?

yes no

53

Date of relapse:54 __ __ __ __ - __ __- __ __

Central nervous system

yes no

55

Cerebrospinal fluid (CSF)

Yes No

56

Parenchyma (brain)

Yes No

57

Mediastinum

Yes No

58

Skin

yes no

59

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

60

Testes / ovaries

Yes No

61

Other site

yes no

62

Specify other site:63

Laboratory Studies at Last Evaluation Prior to the Start of the Preparative Regimen / Infusion Questions: 64 - 91

WBC

Known Unknown

64

65 x 109/L (x 103/mm3)

x 106/L

Date sample collected:66 __ __ __ __ - __ __- __ __

Blasts in blood

Known Unknown

67

68 %

Date sample collected:69 __ __ __ __ - __ __- __ __

Blasts in bone marrow

Known Unknown

70

71 %

Date sample collected:72 __ __ __ __ - __ __- __ __

Was flow cytometry performed?

yes no Unknown

73

Blood

yes no

74

Date sample collected:75 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

76

Specify percent disease detected:77 %

Bone marrow

yes no

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Specify percent disease detected:81 %

Was extramedullary disease present?

yes no Unknown

82

Central nervous system

yes no

83

Cerebrospinal fluid (CSF)

Yes No

84

Parenchyma (brain)

Yes No

85

Mediastinum

yes no

86

Skin

yes no

87

Soft tissue (soft tissue mass / granulocytic sarcoma)

yes no

88

Testes / ovaries

Yes No

89

Other site

yes no

90

Specify other site:91

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

Specify site(s) of disease:

Specify prophylaxis:

Specify site(s) of radiation therapy:

Specify CNS irradiation:

Specify sites of disease relapse:

Specify tissue and results at last evaluation prior to the start of the preparative regimen:

Specify site(s) of disease:

Center: CRID: 

Form 2011 R5.0: Acute Lymphoblastic Leukemia (ALL) Pre-Infusion Data

CIBMTR Form 2011 revision 5.0 last updated Monday, July 17, 2017
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 4